1. Home
  2. GERN vs HIPO Comparison

GERN vs HIPO Comparison

Compare GERN & HIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • HIPO
  • Stock Information
  • Founded
  • GERN 1990
  • HIPO 2015
  • Country
  • GERN United States
  • HIPO United States
  • Employees
  • GERN N/A
  • HIPO N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • HIPO Property-Casualty Insurers
  • Sector
  • GERN Health Care
  • HIPO Finance
  • Exchange
  • GERN Nasdaq
  • HIPO Nasdaq
  • Market Cap
  • GERN 823.0M
  • HIPO 842.4M
  • IPO Year
  • GERN 1996
  • HIPO N/A
  • Fundamental
  • Price
  • GERN $1.27
  • HIPO $36.98
  • Analyst Decision
  • GERN Buy
  • HIPO Strong Buy
  • Analyst Count
  • GERN 8
  • HIPO 5
  • Target Price
  • GERN $3.71
  • HIPO $34.40
  • AVG Volume (30 Days)
  • GERN 5.5M
  • HIPO 186.8K
  • Earning Date
  • GERN 11-06-2025
  • HIPO 11-07-2025
  • Dividend Yield
  • GERN N/A
  • HIPO N/A
  • EPS Growth
  • GERN N/A
  • HIPO N/A
  • EPS
  • GERN N/A
  • HIPO N/A
  • Revenue
  • GERN $164,447,000.00
  • HIPO $425,000,000.00
  • Revenue This Year
  • GERN $175.15
  • HIPO $27.97
  • Revenue Next Year
  • GERN $56.61
  • HIPO $25.47
  • P/E Ratio
  • GERN N/A
  • HIPO N/A
  • Revenue Growth
  • GERN 11877.20
  • HIPO 43.15
  • 52 Week Low
  • GERN $1.09
  • HIPO $15.74
  • 52 Week High
  • GERN $4.83
  • HIPO $38.98
  • Technical
  • Relative Strength Index (RSI)
  • GERN 41.64
  • HIPO 67.02
  • Support Level
  • GERN $1.23
  • HIPO $36.13
  • Resistance Level
  • GERN $1.33
  • HIPO $38.98
  • Average True Range (ATR)
  • GERN 0.07
  • HIPO 1.51
  • MACD
  • GERN -0.02
  • HIPO 0.13
  • Stochastic Oscillator
  • GERN 13.79
  • HIPO 71.35

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

Share on Social Networks: